Knowledge
Comprehensive information, brochures and resources about amyloidosis
Current Research
CARES Study: Anselamimab in AL Amyloidosis
July 2025
On July 16, 2025, AstraZeneca presented interim results of the CARES Phase III program for the treatment of AL amyloidosis. In the overall group of patients with advanced disease (Mayo stages IIIa/IIIb), the antibody anselamimab could not significantly improve the primary endpoint – a combined assessment of overall survival and cardiovascular hospitalizations. However, in a predefined subgroup, it showed a clinically relevant extension of survival and fewer cardiac hospitalizations compared to placebo. The 406 study participants received anselamimab or placebo in addition to standard therapy; the treatment was well tolerated. Anselamimab is a novel anti-fibril antibody for the reduction of amyloid deposits; further analyses are ongoing, and the data will be presented at scientific conferences and submitted to regulatory authorities.
Brochures on Transthyretin Amyloidosis with Cardiomyopathy
Brochures on Transthyretin Amyloidosis with Polyneuropathy
Our information brochures about Transthyretin Amyloidosis with Polyneuropathy (ATTR-PN) are available. These comprehensive guides provide important information about this form of amyloidosis.
Brochures on Immunoglobulin Light Chain Amyloidosis
Guide for Movement and Training in Amyloidosis
Our brochure offers practical instructions for physical activity and training in amyloidosis. This guide helps those affected improve their quality of life and slow disease progression through adapted exercises.
Information Event 2024
Summary of our information event on November 2, 2024 at Lucerne Cantonal Hospital
Speakers Summary
PD Dr. med. Simon Stämpfli
Co-Chefarzt Kardiologie, LUKS
Neue Behandlungsoptionen Amyloidose
Dr. med. Rahel Schwotzer
Leitende Oberärztin, Klinik für Medizinische Onkologie und Hämatologie, USZ
Moderne Therapiemöglichkeiten der AL-Amyloidose
PD Dr. med. Alexander Breitenstein
Leitender Arzt, Klinik für Kardiologie, USZ
Herzschrittmacher bei Amyloidose
Additional Resources
Discover more resources and information about amyloidosis.
Questions?
Do you have questions about the content or need further information? Feel free to contact us.